.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,217,974

« Back to Dashboard

Claims for Patent: 5,217,974

Title: Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
Abstract:Administration of a folate binding protein binding agent in conjunction with use of an antitumor agent which is an inhibitor of glycinamide ribonucleotide transformylase or other antifolate reduces the toxic effects of such agent and provides an enhanced therapeutic index.
Inventor(s): Grindey; Gerald B. (Indianapolis, IN), Shih; Chuan (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:07/940,568
Patent Claims: 1. A method of inhibiting the growth of GAR-transformylase-dependent tumors in mammals comprising administering to said mammals an effective amount of a GAR-transformylase inhibitor which binds to a folate binding protein in combination with a toxicity-reducing amount of a folate binding protein binding agent selected from folic acid, (6R)-5-methyl-5,6,7,8-tetrahydrofolic acid, and (6R)-5-formyl-5,6,7,8-tetrahydrofolic acid, or a physiologically-available salt or ester thereof.

2. The method of claim 1 wherein the GAR-transformylase inhibitor is a pyrido[2,3-d]pyrimidine.

3. The method of claim 2 wherein the GAR-transformylase inhibitor is lometrexol.

4. The method of claim 1 wherein the folate binding protein binding agent is folic acid.

5. The method of claim 3 wherein the folate binding protein binding agent is folic acid.

6. The method of claim 5 wherein the folic acid is administered at a dose of about 0.5 mg/day to about 30 mg/day.

7. The method of claim 5 wherein the folic acid is administered at a dose of about 1 mg/day to about 5 mg/day.

8. A method for reducing mammalian toxicity of a GAR-transformylase inhibitor which binds to a folate binding protein consisting of administering a toxicity reducing amount of a folate binding protein binding agent selected from folic acid, (6R)-5-methyl-5,6,7,8-tetrahydrofolic acid, and (6R)-5-formyl-5,6,7,8-tetrahydrofolic acid, or a physiologically-available salt or ester thereof, to the mammal receiving treatment with the GAR-transformylase inhibitor.

9. The method of claim 8 wherein the GAR-transformylase inhibitor is a pyrido[2,3-d]pyrimidine.

10. The method of claim 9 wherein the GAR-transformylase inhibitor is lometrexol.

11. The method of claim 8 wherein the folate binding protein binding agent is folic acid.

12. The method of claim 11 wherein folic acid is administered at a dose of about 0.5 mg/day to about 30 mg/day.

13. The method of claim 12 wherein folic acid is administered at a dose of about 1 mg/day to about 5 mg/day.

14. The method of claim 8 wherein the folate binding protein binding agent is (6R)-5-methyl-5,6,7,8-tetrahydrofolic acid or a physiologically-available salt or ester thereof.

15. The method of claim 8 wherein the folate binding protein binding agent is (6R)-5-formyl-5,6,7,8-tetrahydrofolic acid or a physiologically-available salt or ester thereof.

16. A method for reducing the toxicity of a GAR-transformylase inhibitor or other antifolate which binds to a folate binding protein in a mammal which comprises pretreating the mammal with an amount of a folate binding protein binding agent selected from folic acid, (6R)-5-methyl-5,6,7,8-tetrahydrofolic acid, and (6R)-5-formyl-5,6,7,8-tetrahydrofolic acid, or a physiologically available salt or ester thereof, sufficient to have substantially blocked the folate binding protein before administration of the antifolate.

17. The method of claim 16 wherein the GAR-transformylase inhibitor is lomotrexol.

18. The method of claim 16 wherein the folate binding protein binding agent is folic acid.

19. The method of claim 18 wherein the folic acid is administered about 1 to about 24 hours prior to administration of the antifolate.

20. The method of claim 19 wherein a dose of about 0.5 mg to about 30 mg of folic acid is administered.

21. The method of claim 10 wherein the folate binding protein binding agent is folic acid, or a physiologically-available salt or ester thereof.

22. The method of claim 17 wherein the folate binding protein binding agent is folic acid, or a physiologically-available salt or ester thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc